International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

Cellular Effects of Troglitazone on YD15 Tongue Carcinoma Cells

  • Loan, Ta Thi (Department of Pharmacology and Dental Therapeutics, College of Dentistry, Chosun University) ;
  • Yoo, Hoon (Department of Pharmacology and Dental Therapeutics, College of Dentistry, Chosun University)
  • Received : 2016.06.23
  • Accepted : 2016.08.05
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

An FDA approved drug for the treatment of type II diabetes, Troglitazone (TRO), a peroxisome proliferator-activated receptor gamma agonist, is withdrawn due to severe idiosyncratic hepatotoxicity. In the search for new applications of TRO, we investigated the cellular effects of TRO on YD15 tongue carcinoma cells. TRO suppressed the growth of YD15 cells in the MTT assay. The inhibition of cell growth was accompanied by the induction of cell cycle arrest at $G_0/G_1$ and apoptosis, which are confirmed by flow cytometry and western blotting. TRO also suppressed the expression of cell cycle proteins such as cyclin D1, cdk2, cdk4, cyclin B1, cdk1(or cdc2), cyclin E1 and cyclin A. The inhibition of cell cycle proteins was coincident with the up-regulation of $p21^{CIP1/WAF1}$ and $p27^{KIP1}$. In addition, TRO induces the activation of caspase-3 and caspase-7, as well as the cleavage of PARP. Further, TRO suppressed the expressions of Bcl-2 without affecting the expressions of Bad and Bax. Overall, our data supports that TRO induces cell cycle arrest and apoptosis on YD15 cells.

Keywords

References

  1. Duvvuri U, Myers JN. Cancer of the head and neck is the sixth most common cancer worldwide. Curr Probl Surg. 2009, 46, 114-117. doi: 10.1067/j.cpsurg.2008.10.002.
  2. Petersen PE. Strengthening the prevention of oral cancer: the WHO perspective. Community Dent Oral Epidemiol. 2005, 33, 397-399. doi: 10.1111/j.1600-0528.2005.00251.x.
  3. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado M P, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009, 18, 541-550. doi: 10.1158/1055-9965.EPI-08-0347.
  4. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007, 356, 1944-1956. doi: 10.1056/NEJMoa065497.
  5. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988, 48, 3282-3287.
  6. Remmerbach TW, Weidenbach H, Pomjanski N, Knops K, Mathes S, Hemprich A, Bocking A. Cytologic and DNA-cytometric early diagnosis of oral cancer. Anal Cell Pathol. 2001, 22, 211-221. doi: 10.1155/2001/807358.
  7. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H. High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig 2007, 11, 93-99. doi: 10.1007/s00784-006-0086-8.
  8. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res 2003, 9, 4287-4295.
  9. Okamoto M, Nishimine M, Kishi M, Kirita T, Sugimura M, Nakamura M, Konishi N. Prediction of delayed neck metastasis in patients with stage I/II squamous cell carcinoma of the tongue. J Oral Pathol Med. 2002, 31, 227-233. doi: 10.1034/j.1600-0714.2002.310406.x.
  10. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Ora.l Med Oral Pathol Oral Radiol Endod. 2006, 102, 67-76. doi: 10.1016/j.tripleo.2005.07.038.
  11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995, 270, 12953-12956. doi: 10.1074/jbc.270.22.12953.
  12. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998, 58, 3344-3352.
  13. Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N, Kohgo Y. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res. 2002, 93, 774-782. doi: 10.1111/j.1349-7006.2002.tb01319.x.
  14. Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, Okumura T. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer. 2004, 108, 41-46. doi: 10.1002/ijc.11561.
  15. Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM and Yin ZF. Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol. 2008, 14, 2168-2173. doi: 10.3748/wjg.14.2168.
  16. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ and Law RE. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001, 286, 916-922. DOI:10.1006/bbrc.2001.5491
  17. Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol. 2006, 209, 428-438. doi: 10.1002/jcp.20738.
  18. Ye J, Yin L, Xie P, Wu J, Huang J, Zhou G, Xu H, Lu E, He X. Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro. Onco Targets Ther 2015, 8, 1211-1218. doi: 10.2147/OTT.S79899.
  19. Rousseau A, Lim MS, Lin Z, Jordan RC. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol. 2001, 37, 268-275. doi: 10.1016/S1368-8375(00)00114-7.
  20. Nimeus E, Baldetorp B, Bendahl PO, Rennstam K, Wennerberg J, Akervall J and Ferno M. Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck. Oral Oncol. 2004, 40, 624-629. doi: 10.1016/j.oraloncology.2003.12.014.
  21. Donjerkovic D, Scott DW. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 2000, 10, 1-16. doi: 10.1038/sj.cr.7290031.
  22. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 1992, 257, 1958-1961. doi: 10.1126/science.1329201.
  23. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005, 65, 3980-3985. doi: 10.1158/0008-5472.CAN-04-3995.
  24. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M. Involvement of p21 (WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazoneinduced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001, 33, 1087-1097. doi:10.1053/jhep.2001.24024.
  25. Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, Yook JI. Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005, 37, 379-390. doi:10.1038/emm.2005.48
  26. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007, 35, 495-516. doi: 10.1080/01926230701320337.
  27. Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q, Pan XL, Song YQ, Zhang MH, Hou, Chen F. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol. 2005, 16, 455-459. doi: 10.1093/annonc/mdi077.